Importance There is a critical need for careful and independent validation of reported
symptomatic efficacy and dopaminergic biomarker changes induced by nilotinib in Parkinson …

Background: As the international community dealt with the ongoing COVID-19 pandemic,
important progress continued to be made in the development of new drug-based therapies for …

Background: The majority of current pharmacological treatments for Parkinson’s disease (PD)
were approved for clinical use in the second half of the last century and they only provide …

Background: Despite the COVID-19 pandemic, there has been considerable activity in the
clinical development of novel and improved drug-based therapies for the neurodegenerative …

Background: Since 2020, annual reports on the clinical development of new drug-based
therapies for the neurodegenerative condition of Parkinson’s disease (PD) have been …

Objective Disease modification in Parkinson disease (PD) has remained an elusive goal, in
spite of large investments over several decades. Following a large meeting of experts, this …

Background Personal information, including health-related data, may be used in ways we did
not intend when it was originally shared. However, the organizations that collect these data …

Introduction Parkinson’s disease (PD) is a debilitating neurological disorder for which the
identification of disease-modifying interventions represents a major unmet need. Diverse trial …

Background Nilotinib, a tyrosine kinase Abelson inhibitor, exhibits neuroprotective effects in
preclinical Parkinson disease (PD) models. Methods This Phase 2A double-blind placebo-…

Background: Design of disease modification (DM) trials for Parkinson’s disease (PD) is
challenging. Successful delivery requires a shared understanding of priorities and practicalities. …